University Hospital, Martin
Clinical trials sponsored by University Hospital, Martin, explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Simple blood test may replace biopsies for kidney rejection detection Results expected Nov 2026 (estimated)
- New hope for kidney transplants: drug targets hidden inflammation Results expected Mar 2027 (estimated)
-
Can a gut metabolite shield the kidneys in IgA nephropathy?
Disease control By invitation onlyThis trial tests whether sodium butyrate, a short-chain fatty acid, can reduce protein in the urine and slow kidney function decline in people with IgA nephropathy, a kidney disease. Participants receive either sodium butyrate or a placebo for 12 weeks, then switch after a washou…
Early phase 1 • Sponsor: University Hospital, Martin • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
New hope for kidney transplants: drug targets hidden inflammation
Disease control OngoingThis study tests whether daratumumab can reduce microvascular inflammation in kidney transplant recipients. Twenty adults with signs of inflammation on biopsy will either receive daratumumab or standard monitoring. The goal is to see if the drug improves kidney health over 12 mon…
Phase 4 • Sponsor: University Hospital, Martin • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC